Cencora (NYSE:COR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Cencora (NYSE:COR) had its price objective hoisted by equities research analysts at JPMorgan Chase & Co. from $344.00 to $417.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 14.10% from the company’s current price.

A number of other research firms have also recently weighed in on COR. UBS Group boosted their price objective on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday. Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Mizuho upped their target price on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $371.09.

Cencora Trading Up 0.2%

COR stock traded up $0.81 during midday trading on Tuesday, reaching $365.46. 126,395 shares of the company traded hands, compared to its average volume of 1,535,519. The firm has a market capitalization of $70.85 billion, a price-to-earnings ratio of 37.51, a P/E/G ratio of 1.56 and a beta of 0.63. Cencora has a 52-week low of $223.92 and a 52-week high of $366.17. The business has a 50 day moving average of $315.73 and a 200-day moving average of $300.12. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts expect that Cencora will post 15.37 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 41,544 shares of company stock valued at $12,230,941. 10.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cencora

Several large investors have recently modified their holdings of the business. Atlantic Edge Private Wealth Management LLC boosted its stake in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares in the last quarter. Costello Asset Management INC purchased a new stake in Cencora during the first quarter worth $28,000. Vermillion & White Wealth Management Group LLC boosted its position in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after acquiring an additional 43 shares in the last quarter. Cloud Capital Management LLC purchased a new position in shares of Cencora in the 3rd quarter valued at $31,000. Finally, Westside Investment Management Inc. raised its position in shares of Cencora by 200.0% in the 3rd quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock worth $33,000 after acquiring an additional 70 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.